ARNA Financial Facts
Cost of manufacturing services: 1.65MOther: 32K
See Full Income Statement
Derivative liabilities, less current portion: 10.19M
Acquired technology and other intangibles, net: 10.07M
See Full Balance Sheet
Earnings History for Arena Pharmaceuticals, Inc. (ARNA)
|
Expand Research on ARNA
| Next EPS Date | 8/8/13 *Est. | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -69.8% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +4.6% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/2/13 |
Q113 | $0.09 | $0.11 | -$0.02 | N/A | $50.36M | N/A / N/A | N/A | -4.6% | Details | |
| 3/4/13 |
Q412 | -$0.10 | -$0.03 | -$0.07 | $1.94M | $21.94M | N/A / N/A | N/A | -4% | Details | |
| 11/6/12 |
Q312 | -$0.07 | -$0.09 | +$0.02 | $1.49M | $3.51M | N/A / N/A | N/A | +5.8% | Details | |
| 8/9/12 |
Q212 | -$0.12 | -$0.08 | -$0.04 | $22M | $7.38M | N/A / N/A | N/A | +8.1% | Details | |
| 3/14/12 |
Q411 | -$0.16 | -$0.15 | -$0.01 | $2.08M | $3.49M | N/A / N/A | N/A | +347.5% | Details | |
| 11/9/11 |
Q311 | -$0.16 | -$0.14 | -$0.02 | $3.46M | $3.37M | N/A / N/A | N/A | +489% | Details | |
| 8/9/11 |
Q211 | -$0.16 | -$0.16 | $0.00 | $3.26M | $3.35M | N/A / N/A | N/A | +472.1% | Details | |
| 5/10/11 |
Q111 | -$0.35 | -$0.21 | -$0.14 | $3.92M | $3.29M | N/A / N/A | N/A | +493.3% | Details |
